This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
R Coombes (2014). Cannabis regulation: high time for change? British Medical Journal 348, g3382.
VH Curran , C Brignell , S Fletcher , P Middleton , J Henry (2002). Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61–70.
M Di Forti , A Marconi , E Carra , S Fraietta , A Trotta , M Bonomo , F Bianconi , P Gardner-Sood , J O'Connor , M Russo (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2, 233–238.
M Di Forti , C Morgan , P Dazzan , C Pariante , V Mondelli , TR Marques , R Handley , S Luzi , M Russo , A Paparelli (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488–491.
M Di Forti , H Sallis , F Allegri , A Trotta , L Ferraro , SA Stilo , A Marconi , C La Cascia , TR Marques , C Pariante (2013). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 1509–1517.
DC D'Souza , E Perry , L MacDougall , Y Ammerman , T Cooper , Y-T Wu , G Braley , R Gueorguieva , JH Krystal (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558–1572.
A Englund , PD Morrison , J Nottage , D Hague , F Kane , S Bonaccorso , JM Stone , A Reichenberg , R Brenneisen , D Holt (2012). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology 27, 19–27.
M Field , WM Cox (2008). Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug and Alcohol Dependence 97, 1–20.
TP Freeman , CJ Morgan , C Hindocha , G Schafer , RK Das , HV Curran (2014). Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 109, 1686–1694.
M Gossop , S Darke , P Griffiths , J Hando , B Powis , W Hall , J Strang (1995). The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90, 607–614.
C Hindocha , TP Freeman , G Schafer , C Gardener , RK Das , CJ Morgan , HV Curran (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology 25, 325–334.
Z Justinova , G Tanda , GH Redhi , SR Goldberg (2003). Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169, 135–140.
CJ Morgan , G Schafer , TP Freeman , HV Curran (2010 a). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. British Journal of Psychiatry 197, 285–290.
CJA Morgan , HV Curran (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. British Journal of Psychiatry 192, 306–307.
CJA Morgan , TP Freeman , GL Schafer , HV Curran (2010 b). Cannabidiol attenuates the appetitive effects of [Delta]9-Tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35, 1879–1885.
F Pijlman , S Rigter , J Hoek , H Goldschmidt , R Niesink (2005). Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology 10, 171–180.
DJ Potter (2014). A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Testing and Analysis 6, 31–38.
DJ Potter , P Clark , MB Brown (2008). Potency of Δ9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. Journal of Forensic Sciences 53, 90–94.
GR Potter , C Chatwin (2012). The problem with ‘skunk’. Drugs and Alcohol Today 12, 232–240.
EB Russo (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163, 1344–1364.
W Swift , J Copeland , W Hall (1998). Choosing a diagnostic cut-off for cannabis dependence. Addiction 93, 1681–1692.
P van der Pol , N Liebregts , T Brunt , J Amsterdam , R Graaf , DJ Korf , W Brink , M Laar (2014). Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109, 1101–1109.
P van der Pol , N Liebregts , R de Graaf , DJ Korf , W van den Brink & M van Laar (2013). Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug and Alcohol Dependence 133, 352–359.
AR Winstock , LR Mitcheson , P Deluca , Z Davey , O Corazza , F Schifano (2011). Mephedrone, new kid for the chop? Addiction 106, 154–161.
A Zuardi , I Shirakawa , E Finkelfarb , I Karniol (1982). Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology 76, 245–250.